Related Experiment Video
Updated: Feb 11, 2026

Orthotopic Mouse Model of Colorectal Cancer
Published on: December 4, 2007
Dynamic Biomarkers of Response to Antiangiogenic Therapies in Colorectal Cancer: A Review
Jesus Rodriguez-Pascual1, Antonio Cubillo1
1Centro Integral Oncológico Clara Campal (CIOCC), Madrid, Spain.
Background:
Identification of clinical and molecular biomarkers to predict dynamic response or monitor in real-time the efficacy of antiangiogenic therapy represents a major point in the treatment of patients with advanced colorectal cancer. Several stu-dies have been conduced to identify some predictive biomarkers to select patients who will benefit from bevacizumab, the most widely used antiangiogenic monoclonal anti-body.
Conclusion:
After a decade since the introduction of bevacizumab, no effective predictive biomarkers are available in routine clinical practice. In this review, we summarized the potential candidate dynamic biomarkers that may play a role in this setting.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Gene Therapy
Dynamic Equilibrium

